Neurocrine Biosciences Inc (NBIX)

Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA and an Investment Account
Sell

$100.00

Buy

$135.09

arrow-down$-1.81 (-1.54%)

Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
Prices updated at 09 May 2025, 22:13 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up0%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Dr. William H. Rastetter,PhD
CEO
Dr. Kyle W. Gano, PhD
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
1,800
Head office
6027 Edgewood Bend Court
San Diego
United States
92130
mobile
+1 858 617-7600
letter
ir@neurocrine.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Dr. Eiry W. Roberts, M.D.
Chief Medical Officer
0.69m0.51m-6.76m-
Mr. Gary A. Lyons
Independent Director
0.07m--0.47m-
Dr. Kevin C. Gorman,PhD
Director
0.78m1.14m-16.02m-
Mr. Richard F. Pops
Independent Director
0.09m--0.49m-
Ms. Shalini Sharp
Independent Director
0.10m--0.50m-
Dr. William H. Rastetter,PhD
Chairman of the Board
0.10m--0.50m-
Ms. Christine A. Poon
Independent Director
0.08m--0.48m-
Mr. George J. Morrow
Independent Director
0.08m--0.48m-
Dr. Stephen A. Sherwin, M.D.
Independent Director
0.09m--0.49m-
Mr. Eric S. Benevich
Chief Commercial Officer
0.64m0.37m-6.31m-
Mr. Darin M. Lippoldt
Chief Legal Officer and Corporate Secretary
-----
Ms. Leslie V. Norwalk, Esq.
Independent Director
0.08m--0.48m-
Dr. Kyle W. Gano, PhD
Director, President and Chief Executive Officer
0.70m0.54m-8.54m-
Mr. Matthew C. Abernethy
Chief Financial Officer and Principal Accounting Officer
0.68m0.45m-6.60m-
Ms. Julie S. Cooke
Chief Human Resources Officer
-----
Ms. Johanna Mercier
Independent Director
0.07m--0.47m-
Mr. David W. Boyer
Chief Corporate Affairs Officer
-----
Dr. Jude Onyia, PhD
Chief Scientific Officer
0.68m0.51m-7.04m-
Dr. Ingrid Delaet, PhD
Chief Regulatory Officer
-----

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
BlackRock Inc14,782,7220.040835266743.6943930 Apr 202514.94
Vanguard Group Inc10,119,6410.024061226811.22718330 Apr 202510.23
BlackRock Fund Advisors7,077,65411.59749-57412-30 Apr 20257.15
State Street Corp4,891,1370.02634-257156-4.99497630 Apr 20254.94
Dodge & Cox Stock Fund3,964,0000.38684189396491.49425430 Apr 20254.01

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
31 Dec 2024-Ms. Ingrid Delaet138.1037,5632,507--
31 Dec 2024-Ms. Ingrid Delaet79.0221,4932,779--
31 Dec 2024-Ms. Ingrid Delaet--2,718--
17 Dec 2024-Dr. Eiry W. Roberts, M.D.--27,770--
17 Dec 2024-Dr. Eiry W. Roberts, M.D.--5,487--
17 Dec 2024-Ms. Ingrid Delaet135.00147,2852,507--
17 Dec 2024-Ms. Ingrid Delaet--2,990--
17 Dec 2024-Ms. Ingrid Delaet79.0286,2113,598--
29 Nov 2024-Dr. Jude Onyia, PhD126.29294,37315,449--
29 Nov 2024-Dr. Jude Onyia, PhD--4,426--
29 Nov 2024-Dr. Jude Onyia, PhD--17,780--
08 Nov 2024-Dr. Eiry W. Roberts, M.D.77.81399,94328,856--
08 Nov 2024-Dr. Eiry W. Roberts, M.D.--1,265--
08 Nov 2024-Dr. Eiry W. Roberts, M.D.-----
08 Nov 2024-Dr. Eiry W. Roberts, M.D.-----
08 Nov 2024-Dr. Eiry W. Roberts, M.D.-----
08 Nov 2024-Dr. Eiry W. Roberts, M.D.79.027931,061--
08 Nov 2024-Dr. Eiry W. Roberts, M.D.102.9099,91631,060--
08 Nov 2024-Dr. Eiry W. Roberts, M.D.81.0599,93530,089--
04 Nov 2024-Dr. Stephen A. Sherwin, M.D.--24,504--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.